All News

Three deaths determined to be result of colchicine toxicity

Maryland pharmacists urge House Majority Leader Hoyer to put patients first

Children are using more medications to treat gastrointestinal problems

The National Association of Boards of Pharmacy has reinstated the North American Pharmacist Licensure Exam at all the Prometric testing centers.

The Centers for Medicare & Medicaid Services has released an improved plan finder with details on 2008 Medicare Part D prescription drug plans.

Two Hispanic pharmacy chains combine under Navarro name

Several manufacturers withdraw over-the-counter cough and cold products

New metabolic warnings added to olanzapine product labels

First oxcarbazepine receives approval for seizure disorders

Battle over ESA coverage continues

Medi-Promotions to launch Medi-Scripts Plus prescription pad

FDA grants full approval of tipranavir.

U.S. payers to incorporate biogeneric agents into their formularies

2008 Medicare Part D premiums to rise 21%, according to study by Avalere Health.

CVS Caremark celebrates American Pharmacists Month

Mipomersen sodium is the new generic name for Isis Pharmaceuticals' anticholesterol drug ISIS 301012.

Aetna's New Jersey e-prescribing pilot shows increase in generics

FDA launches initiative to bolster generic drug program

Low back pain guidelines are released from the American Pain Society and American College of Physicians

FTC cites retail health clinics as having potential to expand.

Instead of giving out separate written information for six infant vaccines, the Centers for Disease Control & Prevention is proposing to combine them into one document.

CMS will begin rejecting Medicare claims that do not use NPI numbers.

Pharmacy and consumer groups approve of new FDA bill that will track drug safety after approval and speed some generic drugs to market.

Combination medication Azor receives FDA approval

Somatropin (Norditropin, Novo Nordisk) approved by FDA for Turner syndrome

President Bush signs law to delay implementation of tamper-resistant prescription pad rule six months

Recordkeeping requirements for chemical distributors may be revised by FDA

The Food and Drug Administration most emphatically is not against compounding of drugs, Steven Silverman, a key enforcement officer in that agency, told the National Association of Boards of Pharmacy recently.